Cargando…

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

PURPOSE: In this study, the formation of cisplatin-DNA adducts after concurrent cisplatin-radiation and the relationship between adduct-formation in primary tumor tissue and normal tissue were investigated. METHODS: Three intravenous cisplatin-regimens, given concurrently with radiation, were studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoebers, F. J. P., Pluim, D., Hart, A. A. M., Verheij, M., Balm, A. J. M., Fons, G., Rasch, C. R. N., Schellens, J. H. M., Stalpers, L. J. A., Bartelink, H., Begg, A. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2007
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270367/ https://www.ncbi.nlm.nih.gov/pubmed/17639394 http://dx.doi.org/10.1007/s00280-007-0545-1

Ejemplares similares

Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei
por: Liedert, Bernd, et al.
Publicado: (2006)

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
por: Schellens, J. H., et al.
Publicado: (1996)

Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.
por: Meijer, C., et al.
Publicado: (1997)

Hydrated electrons induce the formation of interstrand cross-links in DNA modified by cisplatin adducts
por: Behmand, B, et al.
Publicado: (2020)

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)

Postoperative chemoradiotherapy in gastric cancer – a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy
por: Jansen, E P M, et al.
Publicado: (2007)

Cisplatin adducts of DNA as precursors for nanostructured catalyst materials
por: Englert, Klaudia, et al.
Publicado: (2020)

Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts
por: Diggle, C. P., et al.
Publicado: (2005)

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
por: Peng, B., et al.
Publicado: (1997)

Detection and Characterization of Single Cisplatin Adducts on DNA by Nanopore Sequencing
por: Zhao, Xinjia, et al.
Publicado: (2021)

Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo
por: Welters, M J P, et al.
Publicado: (1999)

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
por: Jun, H J, et al.
Publicado: (2008)

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
por: Möckelmann, Nikolaus, et al.
Publicado: (2016)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

Boosting cisplatin chemotherapy by nanomotor-enhanced tumor penetration and DNA adducts formation
por: Xu, Lihua, et al.
Publicado: (2022)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
por: Hettinga, J. V., et al.
Publicado: (1997)

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation
por: Leong, T, et al.
Publicado: (2003)

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
por: Ma, J., et al.
Publicado: (1995)

Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer
por: Kong, Tae Wook, et al.
Publicado: (2012)

HMGB1 bound to cisplatin–DNA adducts undergoes extensive acetylation and phosphorylation in vivo
por: He, Yafeng, et al.
Publicado: (2015)

Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2023)

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
por: Bokemeyer, C., et al.
Publicado: (1996)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin
por: van der Vorst, Maurice J. D. L., et al.
Publicado: (2019)

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
por: Ma, J., et al.
Publicado: (1994)

Tirapazamine-cisplatin: the synergy.
por: Gatzemeier, U., et al.
Publicado: (1998)

Cisplatin/gemcitabine: Lack of efficacy in lung adenocarcinoma: case report
Publicado: (2021)

Quantification of tongue mobility impairment using optical tracking in patients after receiving primary surgery or chemoradiation
por: Kappert, K. D. R., et al.
Publicado: (2019)

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
por: Turner, N C, et al.
Publicado: (2010)

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
por: Bokemeyer, C., et al.
Publicado: (1998)

GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation
por: Pincinato, Eder C., et al.
Publicado: (2019)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

Preferential Cochleotoxicity of Cisplatin
por: Prayuenyong, Pattarawadee, et al.
Publicado: (2021)

Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin–DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model
por: Winardi, Daniel, et al.
Publicado: (2022)

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer
por: Schellens, J H M, et al.
Publicado: (2003)

Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand
por: Tharavichitkul, Ekkasit, et al.
Publicado: (2016)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cthgshsad4kfqdkt369hjcatvu